Rhumbline Advisers Sells 3,063 Shares of Amedisys Inc (AMED)

Rhumbline Advisers lessened its stake in shares of Amedisys Inc (NASDAQ:AMED) by 4.5% during the third quarter, HoldingsChannel reports. The firm owned 65,644 shares of the health services provider’s stock after selling 3,063 shares during the period. Rhumbline Advisers’ holdings in Amedisys were worth $8,203,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Xact Kapitalforvaltning AB increased its stake in shares of Amedisys by 14.1% in the second quarter. Xact Kapitalforvaltning AB now owns 4,851 shares of the health services provider’s stock worth $415,000 after purchasing an additional 600 shares in the last quarter. Amalgamated Bank increased its stake in shares of Amedisys by 13.7% in the second quarter. Amalgamated Bank now owns 4,667 shares of the health services provider’s stock worth $399,000 after purchasing an additional 563 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Amedisys in the second quarter worth about $818,000. Piedmont Investment Advisors LLC increased its stake in shares of Amedisys by 9.3% in the second quarter. Piedmont Investment Advisors LLC now owns 6,668 shares of the health services provider’s stock worth $570,000 after purchasing an additional 567 shares in the last quarter. Finally, Aperio Group LLC increased its stake in shares of Amedisys by 5.1% in the second quarter. Aperio Group LLC now owns 18,079 shares of the health services provider’s stock worth $1,545,000 after purchasing an additional 882 shares in the last quarter. Institutional investors own 90.05% of the company’s stock.

In other Amedisys news, insider David B. Pearce sold 398 shares of Amedisys stock in a transaction that occurred on Friday, November 23rd. The shares were sold at an average price of $119.25, for a total transaction of $47,461.50. Following the completion of the sale, the insider now directly owns 11,420 shares in the company, valued at $1,361,835. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David L. Kemmerly sold 6,500 shares of Amedisys stock in a transaction that occurred on Friday, November 9th. The shares were sold at an average price of $118.87, for a total transaction of $772,655.00. The disclosure for this sale can be found here. Insiders sold 37,486 shares of company stock valued at $4,449,649 over the last 90 days. 2.60% of the stock is owned by company insiders.

Several research firms have recently weighed in on AMED. Cantor Fitzgerald began coverage on shares of Amedisys in a research note on Thursday, September 13th. They issued a “neutral” rating and a $117.00 target price for the company. BidaskClub downgraded shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 16th. ValuEngine upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Robert W. Baird lifted their target price on shares of Amedisys from $105.00 to $120.00 and gave the stock a “neutral” rating in a research note on Thursday, October 11th. Finally, Bank of America set a $139.00 target price on shares of Amedisys and gave the stock a “buy” rating in a research note on Tuesday, September 18th. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Amedisys currently has an average rating of “Buy” and a consensus price target of $107.08.

AMED stock opened at $136.25 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06. Amedisys Inc has a 12 month low of $49.80 and a 12 month high of $138.50. The company has a market capitalization of $4.34 billion, a PE ratio of 41.29, a PEG ratio of 2.03 and a beta of 1.22.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Monday, October 29th. The health services provider reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.18. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. The company had revenue of $417.34 million during the quarter, compared to analyst estimates of $411.05 million. During the same period last year, the business earned $0.56 earnings per share. Amedisys’s revenue was up 11.7% compared to the same quarter last year. Equities research analysts predict that Amedisys Inc will post 3.58 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This article was published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2018/12/02/rhumbline-advisers-sells-3063-shares-of-amedisys-inc-amed.html.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Read More: Capital gains and your 401(k) or IRA

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit